Current Atherosclerosis Reports

, Volume 2, Issue 2, pp 104–109 | Cite as

Antiplatelet therapy in secondary stroke prevention

  • Bradford B. Worrall
  • Karen C. Johnston


This article focuses on recent data about the safety and effectiveness of antiplatelet therapies for secondary stroke prevention. Highlights include a discussion of changes in the professional labeling for aspirin and the results of a low- versus high-dose aspirin trial (Aspirin after Carotid Endarterectomy trial). Safety issues regarding aspirin also are considered. Other topics include a review of recent data on thrombotic thrombocytopenic purpura (TTP) associated with ticlopidine and a brief update on clopidogrel. A summary of discussions related to the European Stroke Prevention Study 2 data and Food and Drug Administration consideration of combination dipyridamole/aspirin therapy are presented.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Smith NM, Pathansali R, Bath PM: Platelets and stroke. Vasc Med 1999, 4(3):165–172.PubMedGoogle Scholar
  2. 2.
    Food and Drug Administration: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register October 23, 1998, 63(205):56802–56819.Google Scholar
  3. 3.
    Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. Stroke 1977, 8(3):301–316.PubMedGoogle Scholar
  4. 4.
    Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. part II: surgical group. Stroke 1978, 9(4):309–318.PubMedGoogle Scholar
  5. 5.
    The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT) of 75 mg Aspirin as Secondary Prophylaxis after Cere-brovascular Ischaemic Events. Lancet 1991, 338:1345–1349.CrossRefGoogle Scholar
  6. 6.
    The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Eng J Med 1991, 325:1261–1266.CrossRefGoogle Scholar
  7. 7.
    ISIS-2 (Second International Study of Infarct Survival) Collabora-tive Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2:349–360.Google Scholar
  8. 8.
    Antiplatelet Trialists: Collaboration secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988, 296:320–331.Google Scholar
  9. 9.
    UK TIA Study Group, A United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: interim results. BMJ 1988, 296:316–320.Google Scholar
  10. 10.
    Johnson ES, Lanes SF, Wentworth CE III, et al.: Metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999, 159:1248–1253.PubMedCrossRefGoogle Scholar
  11. 11.
    Bousser MG, Eschwege E, Haguenau M, et al.: ‘AICLA’ Controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombtic cerebral ischemia. Stroke 1983, 14(1):5–14.PubMedGoogle Scholar
  12. 12.
    Taylor DW, Barnett HJ, Haynes RB, et al.: Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999 June 26, 353(9171):2179–2184.PubMedCrossRefGoogle Scholar
  13. 13.
    Van Gijn J: Low dose aspirin in stroke prevention (Letter). Lancet 1999 June 26, 353(9171):2172–2173.PubMedCrossRefGoogle Scholar
  14. 14.
    Petty GW, Brown RD Jr., Whisnant JP, et al.: Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention: a population based study. Ann Intern Med 1999, 130:14–22.PubMedGoogle Scholar
  15. 15.
    He J, Whelton PK, Vu B, Klag MJ: Aspirin and risk of hemorrhage stroke: a meta-analysis of randomized controlled trial. JAMA 1998, 280:1930–1935.PubMedCrossRefGoogle Scholar
  16. 16.
    Boysen G: Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. J Intern Med 1999, 246:239–245.PubMedCrossRefGoogle Scholar
  17. 17.
    Hass WK, Easton JD, Adams HP, et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989, 321(8):501–507.PubMedCrossRefGoogle Scholar
  18. 18.
    Gent M, Blakely JA, Easton JD, et al.: The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989, I:1215–1220.CrossRefGoogle Scholar
  19. 19.
    Gorelick PB, Leurgans SL, Richardson D, et al.: African American Antiplatelet Stroke Prevention Study (AAASPS): clinical trial design. J Stroke Cerebrovasc Dis 1998, 7(6):426–434.CrossRefPubMedGoogle Scholar
  20. 20.
    Svenson CK: Representation of American blacks in clinical trials of new drugs. JAMA 1989, 29:415–421.Google Scholar
  21. 21.
    Chen DK, Kim JS, Sutton DMC: Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature. Arch Intern Med 8 February 1999, 159:311–314.PubMedCrossRefGoogle Scholar
  22. 22.
    Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al.: Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998, 128(7):541–544.PubMedGoogle Scholar
  23. 23.
    Ticlopidine revised package insert: Roche Laboratories. 2 June, 1998.Google Scholar
  24. 24.
    North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991, 325(7):445–453.CrossRefGoogle Scholar
  25. 25.
    Barnett HJ, Taylor DW, Eliasziw M, et al.: Benefit of carotid end-arterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterec-tomy Trial Collaborators. N Engl J Med 1998, 339(20):1415–1425.PubMedCrossRefGoogle Scholar
  26. 26.
    Wysowski DK, Bacsanyi J: Blood dyscrasias and hematologic reactions in ticlopidine users (Letter). JAMA 1996, 276(12):952.CrossRefGoogle Scholar
  27. 27.
    Barnett HJM, Eliasziw M, Meldrum HE: Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995, 332:238–248.PubMedCrossRefGoogle Scholar
  28. 28.
    Shear NH, Appel C: Prevention of ischemic stroke (Letter). N Engl J Med 1995, 333:460.PubMedCrossRefGoogle Scholar
  29. 29.
    Barnett HJM, Eliasziw M, Meldrum HE: Prevention of ischemic stroke — Reply (Letter). N Engl J Med 1995, 333:460.CrossRefGoogle Scholar
  30. 30.
    US Department of Health and Human Services: Public Health Service; Food and Drug Administration — Center for Drug Evaluation and Research. Clopidogrel bisulfate [Application #020839]. The Electronic Orange Book. Last Updated: September 07, 1999.Google Scholar
  31. 31.
    Gorelick PB, Born GVR, D’Agostino RB, et al.: Therapeutic benefit: aspirin revisited in light of the introduction of clopidogrel. Stroke 1999, 30:1716–1721.PubMedGoogle Scholar
  32. 32.
    FDA press release. Aggrenox™ (Dipyridamole/aspirin) capsule[Original Application #020884]. 15 June 1999.Google Scholar
  33. 33.
    Open Public Hearing of the Peripheral and Central Nervous System Advisory Committee: Issue: Safety and Efficacy of Aggrenox™ (Dipyridamole/aspirin) capsule [NDA 20-884]. Wednesday April 28, 1999.Google Scholar
  34. 34.
    Diener HC, et al.: A European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neuro Sci 1996, 143:1–13.CrossRefGoogle Scholar
  35. 35.
    Sivenius J, Cunha L, Diener H-C, et al.: Second European Stroke Prevention Study: antiplatelet therapy effective regardless of age. Acta Neurol Scand 1999, 99:54–60.PubMedCrossRefGoogle Scholar
  36. 36.
    Sivenius J, Cunha L, Diener HC, et al.: Antiplatelet treatment does not reduce the severity of subsequent stroke. European Stroke Prevention Study 2 Working Group. Neurology 1999, 53(4):825–829.PubMedGoogle Scholar
  37. 37.
    Wilterdink JL, Easton JD: Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 1999, 56(9):1087–1092.PubMedCrossRefGoogle Scholar
  38. 38.
    Herman AG: Rationale for the combination of anti-aggregating drugs. Thromb Res 1998, 92:S17-S21.PubMedCrossRefGoogle Scholar
  39. 39.
    Akyuz A, Bolayir E, Dener S, et al.: The effect of aspirin, ticlopidine and their low-dose combination on platelet aggregability in acute ischemic stroke: a short duration follow-up study. Eur J Neurol 1999, 6(1):57–61.PubMedCrossRefGoogle Scholar
  40. 40.
    Farrell TP, Hayes KB, Sobel BE, Schneider DJ: The lack of augmentation by aspirin of platelet reactivity by ticlopidine. Am J Cardiol 1999, 83:770–774.PubMedCrossRefGoogle Scholar
  41. 41.
    Steinhubl SR, Topol EJ: Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. J Thromb 1999, 7(3):227–231.CrossRefGoogle Scholar
  42. 42.
    Harker LA, Marsec UM, Kelly AB, et al.: Clopidogrel inhibits stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998, 98(22):2461–2469.PubMedGoogle Scholar
  43. 43.
    The PURSUIT Trial Investigators: Inhibition of Platelet glycoprotein IIb/IIIa with Eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998, 339:436–443.CrossRefGoogle Scholar
  44. 44.
    Zhao XQ, Theroux P, Snapinn SM, Sax FL: Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: angiographic results from the PRISM-PLUS trial. Circulation 1999, 100(15):1609–1615.PubMedGoogle Scholar
  45. 45.
    Kereiakes DJ: Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? Am Heart J 1999, 138:S39-S46.PubMedCrossRefGoogle Scholar
  46. 46.
    Madan M, Berkowitz SD: Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999, 138(4 Pt 2):317–326.PubMedCrossRefGoogle Scholar
  47. 47.
    Blankenship JC: Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999, 138(4 Pt 2):287–296.PubMedCrossRefGoogle Scholar
  48. 48.
    Orgogozo JM: Piracetam in the treatment of acute stroke. Pharmacopsychiat 1999, 32(Supplement):25–32.CrossRefGoogle Scholar
  49. 49.
    Coto V, Oliviero U, Cocozza M, Milani M: Long-term safety and efficacy of Picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6 year follow-up study. J Int Med Res 1998, 26:200–205.PubMedGoogle Scholar
  50. 50.
    Cesarone MR, Laurora G, DeSanctis MT, et al.: Effect of Triflusal on arteriosclerosis progression assessed with high-resolution arterial ultrasound. Angiology 1999, 50(6):455–463.PubMedCrossRefGoogle Scholar
  51. 51.
    Yasue H, Ogawa H, Tanaka H, et al.: Effect of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol 1999, 83:1308–1313.PubMedCrossRefGoogle Scholar
  52. 52.
    Albers GW, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998, 114:683S-698S.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Bradford B. Worrall
    • 1
  • Karen C. Johnston
    • 1
  1. 1.Department of NeurologyUniversity of Virginia Health Systems #394CharlottesvilleUSA

Personalised recommendations